The Liver Meeting 2021-Advances in Molecular Therapies and Emerging Treatment in Advanced HCC

Video Transcription

Video Summary

The video discussed various therapies for hepatocellular carcinoma (HCC), emphasizing the molecular rationale for combination therapies, molecular classifications, and genetic alterations for potential targeted therapy. Approved drugs like sorafenib, atezolizumab, Bevacizumab, and emerging therapies in clinical trials were covered. The importance of sequencing active drugs based on patient tolerance and disease progression to improve survival rates was highlighted. Additionally, the video delved into immunotherapies and targeted therapies for HCC like checkpoint inhibitors, VEGF inhibitors, and tyrosine kinase inhibitors, with a focus on managing adverse events, hepatotoxicity, and immune-related adverse events. Strategies to convert cold tumors to hot tumors and considerations for patients with pre-existing autoimmune diseases were discussed. The use of biomarkers for predicting and detecting immune-related adverse events was emphasized, along with risks associated with specific drugs like Avastin. Overall, the video aimed to provide a comprehensive overview of current and emerging therapies for HCC to enhance patient outcomes and survival rates, stressing the importance of a multidisciplinary approach in managing adverse events and treatment strategies for advanced HCC patients.

Keywords

hepatocellular carcinoma

combination therapies

molecular classifications

genetic alterations

sorafenib

atezolizumab

Bevacizumab

clinical trials

sequencing active drugs

immunotherapies

checkpoint inhibitors

VEGF inhibitors